Erez Aminov - May 28, 2024 Form 4 Insider Report for MIRA PHARMACEUTICALS, INC. (MIRA)

Role
Chief Executive Officer, Director
Signature
/s/ Michelle Yanez, Attorney-in-Fact for Erez Aminov
Stock symbol
MIRA
Transactions as of
May 28, 2024
Transactions value $
$0
Form type
4
Date filed
5/30/2024, 06:00 PM
Previous filing
May 22, 2024
Next filing
Aug 15, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MIRA Incentive Stock Options (right to buy) Award $0 +379K +151.6% $0.00 629K May 28, 2024 Common Stock 379K $0.84 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on May 28, 2024.
F2 The stock options were issued to the Reporting Person on May 28, 2024, pursuant to a grant under the Issuer's 2022 Omnibus Incentive Plan, as amended and restated (the "Plan"). The stock options vested in full and became exercisable immediately upon issuance on the grant date, May 28, 2024.
F3 Represents 50,000 stock options that were issued to the Reporting Person on April 28, 2023 that were vested in full and became exercisable on the same date, pursuant to a grant under the Issuer's Plan at an exercise price of $5.00 each, (ii) 150,000 stock options that were issued to the Reporting Person on August 17, 2023, pursuant to a grant under the Issuer's Plan which vested in full on August 17, 2023 at an exercise price of $6.50 each, (iii) 50,000 stock options that were issued to the Reporting Person on August 17, 2023 that vested in full and became exercisable on April 28, 2024, pursuant to a grant under the Issuer's Plan at an exercise price of $6.50 each, and (iv) 379,000 stock options that were issued to the Reporting Person on May 28, 2024 that were vested in full and became exercisable on the same date, pursuant to a grant under the Issuer's Plan at an exercise price of $0.84 each.